The Lennox Building 50
50 Richmond Street South
Dublin D02 FK02
Impiegati a tempo pieno: 292
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Darragh Lyons||Chief Exec. Officer||471,39k||N/D||1981|
|Pat Jennings||Chief Financial Officer||N/D||N/D||N/D|
|Jessica Bergin||Director of Investor Relations & External Reporting||N/D||N/D||N/D|
|Mr. Sean Edward Murphy||Exec. VP||N/D||N/D||1953|
|Dr. Andrew C. von Eschenbach||Chief Medical Adviser||N/D||N/D||1942|
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. The company offers life-saving therapeutics for patients with high unmet medical need; biological therapies, which focuses on oncology, infectious, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis. The company develops, manufactures, and markets injectable drugs; discovers and develops drugs for protein misfolding diseases, such as Alzheimer's and Parkinson's diseases. In addition, it focuses on the therapeutics areas of autoimmune and inflammatory disease, immuno-oncology, haematology, and infectious diseases; and developing medical and fitness software, and platform to eliminate disease-causing bacteria in the gut microbiota. Further, the company leverages nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-medicated diseases; provides company secretarial services; develops medical devices; and offers biopharma consulting. Malin Corporation plc was incorporated in 2014 and is based in Dublin, Ireland.
L'ISS Governance QualityScore di Malin Corporation plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.